$LMNL Short the crap. Tight stop-lossLook left NASDAQ:LMNL on daily.
All the pumps followed by the dumps next day.
Close below open - 78%
Avg. fade - 17%
Avg. low - 28%
We aim 23% on the backside here.
LMNL trade ideas
Tangent school: LMNL BuyLimit@4.99 Break through the trend lineTangent school: LMNL BuyLimit@4.99 Break through the trend line
LMNLI called Liminal BioSciences Inc (NASDAQ:LMNL) recently at $4.40 as a potential big runner due to the PDUFA catalyst. On Friday, just a few minutes before the close, the stock was halted and the U.S. Food & Drug Administration (FDA) announced the approval of Ryplazim® (plasminogen, human-tvmh) ("Ryplazim®") for the treatment of patients with plasminogen deficiency type 1 (hypoplasminogenia) through its subsidiary, Prometic Biotherapeutics Inc., holder of the biological license application ("BLA") for Ryplazim®. With this approval, Ryplazim® becomes the first FDA approved therapy for this rare genetic disorder. The stock closed the after-hours trading gaining more than 55% with 8.2M shares traded. Congratulations to those who bought and profited on LMNL in after-hours, further gains are by no means guaranteed and it never hurts to lock profits in after being up almost 70%. Let's see that $7 break on Monday and see if the stock wants more gains, consolidation, or a pull back.
LMNL up and awaynew catalyst on 4 th of june, FDA approval on ryplazim. this stock has been very weak for a while now. big movement imminent on monday
LMNL to double or quadruple within 6-12 months?DISCLAIMER: I'm not a certified or licensed financial advisor, securities trader, or securities broker; and, this is not intended as financial or securities advice.
Hopefully, my observations are improving. Using two separate 2 over 2 layouts for my version of multiple time frame analysis . Tracking intraday trends in one (5s, 2m, 20m, 2h). Tracking multi-day trends in the other (1D, 4D, 2W, 6W).
From my observations (using a custom Pine script):
It looks to me like LMNL is forming a 2W Cup and Handle, and can rebound from its current $4.90 back to its $10 (2W VWAP) and possibly $20 levels (2W MMA50) (July 1, July 30, Aug 24 of 2020).
mid term +6,000%Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on discovery, development, and commercialization of novel small molecule drug candidates for the treatment of patients suffering from respiratory fibrotic diseases and other fibrotic or inflammatory diseases that have high unmet medical needs
Liminal BioSciences, a risky play85% below the July peak of last year and 99% below its all-time high.
Orbiting a major support level around $4.
A capital injection began in mid-November that is still not properly reflected in price.
Stochastic at the oversold point and RSI close to touching it.
It could give the surprise of giving a significant bounce to the marked lines.
The risk is that it has been trading at a loss for some time.
"Liminal (Nasdaq: LMNL) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel treatments for patients suffering from diseases that have high unmet medical need, including those related to fibrosis in respiratory, liver and kidney diseases."
LMNL subliminal chart messagesLMNL is a biopharma company of no incredible significance, but I thought the chart patterns were worth sharing. First and foremost, look at the runup in volume! Trapped beneath downtrend resistance, I'd venture to guess it's undergoing heavy accumulation. If it breaks through downtrend resistance, upside targets are in the neighborhood of $10 and $15 -- full stop, trade closed. At that point, I would fully exit my positions and wait for more data. If it breaks above the second layer of downtrend resistance with some key fundamental drivers, it could indicate the recent volume is driven by some sort of insider knowledge which puts the company back on the map with a multi-billion dollar valuation once again. I've seen crazier things in the bio sector. Let's see what happens.
Chart not looking good at the momentLooks to continue its slide, possibly towards $3.21 or lower. Hard to find where support might wind up here? Nothing good coming out of that quarterly report for investors to bite into. Revenue dropped 41% YOY, the drawdown on their entire line of credit 29.1mil, growing debt, and the issuance of more convertible debt...not helping here. For the moment this looks to be headed much lower unless and until something positive breaks that investors can grab onto.
Looks to have bottomed, quick retrace to $10.50 or ??Huge volume here, looks to have bottomed, I would say definitely oversold at $3.96, however, let's see what happens after the bell. This could quickly retrace at least to $10.50
LMNL - Breakout soon, first target 11,90$Bullish divergence and big volume, probably insider trading.
any tips or criticism welcome
Full WSJ article on Convalescent PlasmaCatalyst:
-Trump and his mention of plasma
-Full WSJ article on Convalescent Plasma
-Hyping on twitter
TrustYourDD@TrustYourDD
Possible sounds like an FDA approval is gonna drop PR any time now and $LMNL $ADMA $TAK and others have been working on plasma collaborations might be tomorrow might be tonight
www.wsj.com
Collection of Convalescent Plasma + updateLiminal BioSciences Commences Collection of Convalescent Plasma from COVID-19 Recovered Donors
Recent published studies have indicated immune globulin and hyperimmune globulin therapy to have the potential to be one of the treatment options for patients with COVID-19. We are proud to be collecting COVID-19 convalescent plasma to be potentially used in the manufacture of hyperimmune immunoglobulins by third parties and be a part of this historic effort which aims to accelerate a reliable, scalable and sustainable option for patients suffering from the impact of COVID-19.
www.prnewswire.com
Liminal BioSciences (LMNL +105.1%) expects to re-submit biologics licensing application (BLA) with the FDA for its lead plasma-derived Ryplazim (plasminogen) for congenital plasminogen deficiency, during Q3.
The company also anticipates to commence multiple ascending dose Phase 1 study of its lead small molecule product candidate fezagepras (PBI-4050) in second half of the year.
In March 2018, the company received FDA Complete Response Letter BLA for Ryplazim, and identified the need for number of changes in the Chemistry Manufacturing and Controls section.
In October 2018, announced positive feedback from FDA Type-C meeting on Ryplazim BLA.
Plasminogen is a naturally occurring protein that is synthesized by the liver and circulates in the blood, and is vital in wound healing, cell migration, tissue remodeling, angiogenesis and embryogenesis.
seekingalpha.com
Liminal BioSciences Provides Guidance Update on Certain Expected Key Milestones For 2020
we are continuing to execute and move our business forward, and remain committed to providing further updates on certain key expected milestones, as appropriate.
We now expect the following timing for two important priorities of the Company for 2020:
The re-submission of our biologics licensing application (BLA) with the US Food and Drug Administration (FDA) for Ryplazim® (plasminogen) for the treatment of congenital plasminogen deficiency is anticipated to be filed in the third quarter of 2020; and
Our multiple ascending dose (MAD) Phase 1 clinical study of fezagepras is expected to be initiated in the second half of 2020."
www.prnewswire.com
